Genetic predictors of response to systemic therapy in esophagogastric cancer

The incidence of esophagogastric cancer is rapidly rising but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers of drug sensitivity and mechanisms of resistance,...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Discov
Main Authors: Janjigian, Yelena Y., Sanchez-Vega, Francisco, Jonsson, Philip, Chatila, Walid K., Hechtman, Jaclyn F., Ku, Geoffrey Y., Riches, Jamie C., Tuvy, Yaelle, Kundra, Ritika, Bouvier, Nancy, Vakiani, Efsevia, Gao, Jianjiong, Heins, Zachary J., Gross, Benjamin E., Kelsen, David P., Zhang, Liying, Strong, Vivian E., Schattner, Mark, Gerdes, Hans, Coit, Daniel G., Bains, Manjit, Stadler, Zsofia K., Rusch, Valerie W., Jones, David R., Molena, Daniela, Shia, Jinru, Robson, Mark E., Capanu, Marinela, Middha, Sumit, Zehir, Ahmet, Hyman, David M., Scaltriti, Maurizio, Ladanyi, Marc, Rosen, Neal, Ilson, David H., Berger, Michael F., Tang, Laura, Taylor, Barry S., Solit, David B., Schultz, Nikolaus
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813492/
https://ncbi.nlm.nih.gov/pubmed/29122777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0787
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים